Bristol-Myers Squibb announced that the U.S. FDA has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer (SCLC).
The approval makes Opdivo the first and only immuno-oncology treatment option for patients with metastatic small cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.
Small cell lung cancer is one of two main types of lung cancer and accounts for about 10 percent to 15 percent of all lung cancers.
Opdivo is also approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) and recurrent or metastatic squamous cell carcinoma of the head and neck.
Read the press release